Hashiba Toyohiro, Yamahara Hiroyasu, Hirakawa Yosuke, Yano Yasuo, Yamada Yuka, Hara Risa, Tabata Hitoshi, Nangaku Masaomi
Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Nephrology (Carlton). 2025 Mar;30(3):e70020. doi: 10.1111/nep.70020.
Recent progress in gas-sensing technology has enabled the rapid collection and highly sensitive analysis of skin gases associated with body odour. Skin gases can be collected less invasively, more continuously, and less consciously than blood or urine. Patients with end-stage kidney disease (ESKD) have a characteristic uremic odour that fades after initiating kidney replacement therapy. We investigated the potential for objectively and quantitatively evaluating the factors underlying uraemia. Skin gases were collected using a passive flux sampler placed on the forearm, with peak intensities measured using gas chromatography-mass spectrometry (GC/MS). We investigated the changes in skin gases obtained from the haemodialysis (HD) group before and after the first HD session of patients undergoing incident dialysis and compared them between the ESKD groups (HD and non-HD) and the healthy group. Thermal desorption enabled the collection of volatile molecules for 20 min using GC/MS preprocessing. Amongst 137 volatile molecules collected from the HD group (N = 5), 16 were detected in all patients. Aldehydes and alkanes were detected more frequently, and four volatile molecules, including 6-methyl-5-hepten-2-one, were detected in all participants in the ESKD (N = 11) and healthy (N = 7) groups. Benzaldehyde and undecanal showed significantly higher intensities in the ESKD group. Additionally, five unidentified volatile molecules were undetectable after dialysis, suggesting an association with the uremic odour. A comprehensive skin gas analysis technique has enabled the identification of volatile molecules related to ESKD. With a short sampling time, skin gas analysis has potential applications in clinical testing and telemedicine.
气体传感技术的最新进展使得能够快速收集和高度灵敏地分析与体臭相关的皮肤气体。与血液或尿液相比,收集皮肤气体的侵入性更小、更持续且更不易察觉。终末期肾病(ESKD)患者具有特征性的尿毒症气味,在开始肾脏替代治疗后会逐渐消失。我们研究了客观定量评估尿毒症潜在因素的可能性。使用放置在前臂的被动通量采样器收集皮肤气体,通过气相色谱 - 质谱联用仪(GC/MS)测量峰值强度。我们调查了初次透析患者血液透析(HD)组在首次HD治疗前后获得的皮肤气体变化,并在ESKD组(HD和非HD)与健康组之间进行了比较。热脱附能够使用GC/MS预处理收集20分钟的挥发性分子。在从HD组(N = 5)收集的137种挥发性分子中,有16种在所有患者中均被检测到。醛类和烷烃类被检测到的频率更高,在ESKD组(N = 11)和健康组(N = 7)的所有参与者中均检测到了四种挥发性分子,包括6 - 甲基 - 5 - 庚烯 - 2 - 酮。苯甲醛和十一醛在ESKD组中的强度显著更高。此外,有五种未鉴定出的挥发性分子在透析后无法检测到,这表明它们与尿毒症气味有关。一种全面的皮肤气体分析技术已经能够识别与ESKD相关的挥发性分子。由于采样时间短,皮肤气体分析在临床检测和远程医疗中具有潜在应用价值。